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Background
Short stature and hip lesions are typical complications of
juvenile idiopathic arthritis (JIA) especially in systemic
and polyarticular variants with early onset. Recovery of
linear growth is quite often reached as result of biologics
therapy, but use of recombinant growth hormone (rGH)
sometimes is required.
Case report
A 14-year-old girl with severe JIA is under our observa-
tion. Polyarthritis involving the hips joints was formed in
second year of her life. Despite for 8 years of continuous
treatment by DMARDs (methotrexate, cyclosporin A,
leflunomide sequentially), NSAIDs, low doses steroids
(<0.3 mg/kg), i.a.injections arthritis was persistent and
destructive lesions of left hip was developed. Due to
growth retardation rGH treatment 0.05 mg/kg was used
with good results for linear growth, but arthritis has wor-
sened. Infliximab was started on 10th year of disease with
good efficacy after 3 infusions (50%ACR pedi response).
It was discontinued because of severe infusion reactions.
Further adalimumab was applied within 7 months with
achievement of 30% ACR pedi response by the first
3 months and gradual full loss of efficacy. As a third lines
of biologics last 14 months abatacept therapy 10 mg/kg
combined in a low doses steroids <0.1 mg/kg and metho-
trexate 15 mg/m2/week is applied. Efficacy of therapy
was achieved 30% -50% -70% -30% ACR pedi response by
3-6-9-12 months. Loss of efficacy is probably connected
with the resumption of rGH treatment after 9 months of
abatacept use. Dramatic damage in the left hip with total
lysis of femoral head was occurred on MRI and CT hip
scans in parallel increase of disease activity 3 months
later after renewal rGH.
Conclusion
It seems that action of rGH is referred opposite to
action of biologics applied in JIA and may stimulate the
progression of osteonecrosis of femoral head.
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